B. infantis

DIETARY_SUPPLEMENT4 trials

Sponsors

Emanual Maverakis, MD, Johnson & Johnson Consumer Inc. (J&JCI), Helmholtz Zentrum München, University of Aarhus

Conditions

Atopic DermatitisDiabetes Mellitus, Type 1Food AllergiesHealthyHealthy Nutrition

Phase 1

Probiotic Supplementation in Breastfed Newborn Infants

WithdrawnNCT02286999

Emanual Maverakis, MDAtopic Dermatitis, Food Allergies

Start: 2015-10-31End: 2018-01-31Updated: 2019-11-15

Unknown Phase

A Study of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis

CompletedNCT04662619

Johnson & Johnson Consumer Inc. (J&JCI)Healthy

Start: 2020-12-18End: 2024-11-19Updated: 2024-12-16

Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

Active, not recruitingNCT04769037

Helmholtz Zentrum MünchenDiabetes Mellitus, Type 1

Start: 2021-04-22End: 2027-10-31Updated: 2024-12-13

The BEGIN Study Bifidobacterium Infantis to Newborns: Effects of Modulating the Gut Microbial Composition on Growth, Immune Function and Inflammatory Conditions - a Randomized Placebo-controlled Double-blinded Intervention Trial

RecruitingNCT06452199

University of AarhusHealthy, Healthy Nutrition

Start: 2024-06-10End: 2043-11-30Target: 1000Updated: 2024-10-01

Related Papers

Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol

BMJ Open2021-11-0133 citations

Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: study protocol for a randomised controlled trial.

2016-07-226 citations